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Encephalitic viruses in the Family Togaviridae, genus Alphavirus are zoonotic
pathogens that are transmitted via hematophagous arthropods and have a wide-
spread distribution in North, Central and South America and include
Venezuelan equine encephalitis virus (VEEV), Western equine encephalitis
virus (WEEV), Eastern equine encephalitis virus (EEEV). The deficit in speci-
fic antiviral drugs or vaccines for effective treatment or prevention of infection
and disease in humans has prompted the development of recombinant live atten-
uated vaccines utilizing Sindbis virus (SIN), a relatively nonpathogenic al-
phavirus in humans,  as a means for expression all of the structural proteins of
the virulent alphaviruses. The safety and efficacy of these chimeric SIN/VEE
viruses have been extensively evaluated in animal models, including immuno-
deficient mice. The epidemiological distribution of these viruses and the disease
manifestations are  reviewed briefly. Progress in the evaluation of the safety, im-
munogenicity and efficacy of the SIN/VEEV and SIN/EEEV candidate vac-
cines against VEEV and EEEV, respectively, as well as chimeric SIN/RVFV
vaccine candidates and the potential for elucidation of the mechanism of effica-
cy employing mice with selective immunodeficiencies is discussed.
Alfavirusna kimeri~na cjepiva protiv alfavirusnih uzro~nika encefalitisa
Rije~ stru~njaka
Virusi encefalitisa iz porodice Togaviridae, roda Alphavirus su zoonozni
uzro~nicikoje prenose hematofagni ~lankono{ci rasprostranjeni u Sjevernoj,
Centralnoj i Ju`noj Americi te uklju~uju virus venezuelskog konjskog encefali-
tisa (engl. Venezuelan equine encephalitis virus, VEEV), virus zapadnog konj-
skog encefalitisa (engl. Western equine encephalitis virus, WEEV) i virus is-
to~nog konjskog encefalitisa (engl. Eastern equine encephalitis virus, EEEV).
Manjak specifi~nih antivirusnih lijekova ili cjepiva za u~inkovito lije~enje ili
sprje~avanje infekcija i bolesti u ljudi potaklo je razvoj rekombiniranih `ivih
atenuiranih cjepiva koja sadr`e Sindbis virus (SIN), relativno bezopasan al-
favirus za ljude, kao ekspresijski vektor svih strukturalnih proteina virulentnih
alfavirusa. Sigurnost i u~nkovitost ovih kimeri~nih SIN/VEE virusa opse`no je
prou~avana na `ivotinjskim modelima, uklju~uju}i imunodeficijentne mi{eve.
Epidemiolo{ka rasprostranjenost ovih virusa i manifestacije bolesti ukratko su
opisane. Raspravlja se o postignutom napretku u ocjenjivanju sigurnosti,
imunogeni~nosti i u~inkovitosti SIN/VEEV i SIN/EEEV potencijalnih cjepiva
protiv VEEV odnosno EEEV, kao i potencijalnih kimeri~nih SIN/RVFV cjepiva
te mogu}e razja{njenje mehanizma djelotvornosti koriste}i mi{eve selektivne
imunodeficijentnosti.
Epidemiology of encephalitic alphaviruses
Geographic distribution
Encephalitic viruses in the Family Togaviridae, genus
Alphavirus are zoonotic pathogens that are transmitted via
hematophagous arthropods and have a widespread distrib-
ution in North, Central and South America (reviewed in
[1]). These viruses also are highly infectious via the
aerosol route, thus have been responsible for numerous lab-
oratory accidents (>150 documented cases without an as-
sociated perforating injury) and have been developed as a
biological weapon in the U.S and in the former Soviet
Union. These alphaviruses were first isolated in the 1930s
from diseased horses in California, in Virginia and New
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Jersey, and from an infected child in Caracas, Venezuela,
and were subsequently named based on their region of iso-
lation as Western equine encephalomyelitis virus (WEEV),
Eastern equine encephalomyelitis virus (EEEV) and
Venezuelan equine encephalomyelitis virus (VEEV), re-
spectively. Subsequently, additional isolates have been ob-
tained from infected mosquitoes, horses, humans, and oth-
er vertebrate species, mainly birds and rodents. Western
equine encephalitis virus is distributed from the mid-
Western states of Michigan and Illinois to the West coast
and clinical cases have been reported in 21 states while
EEEV is distributed from Texas to Florida along the Gulf
coast and from Georgia to New Hampshire along the
Atlantic Coast, with cases reported in 19 states, including
the mid-Western states of Wisconsin, Illinois and
Michigan. The transmission cycle and detailed distribution
are described in [2], and are not covered in this review.
Disease
WEEV, EEEV and VEEV can be neuroinvasive and
cause a range of mild to severe neurological symptoms.
The alphaviruses WEEV, EEEV, VEEV and, more rarely,
Ross River virus, Chikungunya virus and Highlands J virus
(HJV) can cause encephalitis in equines or humans [1].
Venezuelan equine encephalitis virus (VEEV)
VEEV has an incubation period of 2—10 days, which re-
sults typically in non-specific flu-like symptoms, as with
EEEV and WEEV. Severe encephalitis is a less common
outcome of VEEV infection in comparison to EEEV and
WEEV infection, although VEEV-associated encephalitis
is a more common outcome in children. Neurological dis-
ease, including disorientation, ataxia, mental depression,
and convulsions can be detected in up to 14 % of infected
individuals, especially children, although the human case-
-fatality rate is low (< 1 %). Neurological sequelae of en-
cephalitis are common. The predominant pathological
findings in fatal human VEE cases include edema, conges-
tion, hemorrhages, vasculitis, meningitis and encephalitis
in the CNS; interstitial pneumonia, alveolar hemorrhage,
congestion and edema in the lungs; follicular necrosis and
lymphocyte depletion in lymphoid tissue; and diffuse hepa-
tocellular degeneration [1].
Eastern equine encephalitis virus (EEEV)
EEEV has an incubation period of 4—10 days and the in-
fection may lead to sudden onset of fever, general muscle
pains, and headache of increasing severity. In human cases
of encephalitis, fever, headache, vomiting, respiratory
symptoms, leucocytosis, hematuria, seizures and coma
may occur. EEEV is considered to be the most virulent of
the encephalitic alphaviruses, with a case-fatality rate esti-
mated at > 33 %. Clinical imaging studies of serologically-
-confirmed human EEEV infection detect changes in the
basal ganglia and thalami, suggesting brain edema, is-
chemia and hypoperfusion in the early stage of disease.
Gross pathological examination of fatal human cases
demonstrated brain edema with necrosis, facial or genera-
lized edema, vascular congestion and hemorrhage in the
brain and visceral organs. Histopathological observations
of the brain include vasculitis, hemorrhage and encephali-
tis [1].
Western equine encephalitis virus (WEEV)
WEEV has an incubation period of 2—7 days, and the in-
fection may result in mild disease with non-specific symp-
toms, e.g., sudden onset of fever, headache, nausea, vomit-
ing, anorexia and malaise, and in some cases, more severe
neurological signs. Encephalitis or meningo-encephalo-
myelitis occurs in a minority of infected individuals, result-
ing in neck stiffness, confusion, tonic-clonic seizures, som-
nolence, coma and death. Neurological sequelae of 5—30 %
has been reported in survivors of encephalitis, in particular
among children < 1 year old. Serological studies suggest an
age-associated relationship between inapparent to apparent
infections, with significantly increased ratio for children
over age 14. The overall case-fatality rate is about 3 %.
Encephalitis due to WEEV is characterized by a vasculitis
and focal hemorrhages mainly affecting the basal ganglia
and the nucleus of the thalamus, which may be mistaken for
resolved infarcts in elderly patients [1].
Sindbis virus-based chimeric vaccine approach
Recombinant live-attenuated vaccines and, in particu-
lar, an alphavirus-based approach, represent a viable ap-
proach to the production of safe, immunogenic and effica-
cious vaccines against the encephalitis alphaviruses [3—7].
Alphavirus genomes are relatively easy to manipulate, and
infectious clones are available for construction and in vitro
transcription of recombinant viruses for vaccine produc-
tion by cell transfection [8]. By utilizing as a vector the
genome of Sindbis virus (SINV), a relatively nonpathoge-
nic alphavirus in humans, chimeric SIN/VEE virus(es) can
be designed to express all of the structural proteins of the
virulent alphavirus. These constructs contain the cis-acting
RNA elements and non-structural protein genes of the
SINV genome, which are required for replication and tran-
scription of the subgenomic RNA, e.g., 5' untranslated re-
gion (UTR), 3' UTR, and the subgenomic promoter. The
promoter element, located upstream of the subgenomic
RNA transcription start, and the four 5' terminal nucleoti-
des of the subgenomic RNA encompass the end of nsP4
and the termination codon of the nsP-coding open reading
frame (schematically depicted in [7]). 
For VEEV, this approach has been used to evaluate a
variety of representatives among the different VEEV
serotypes (epidemic and endemic strains). For EEEV, vac-
cine candidates were developed using structural protein
genes from a North American (NA) EEEV strain and from
a naturally attenuated Brazilian (SA) EEEV isolate [3].
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Following electroporation of the in vitro transcribed RNA,
these chimeric SIN/VEE and SIN/EEE viruses replicate to
high titer in the commonly used and readily available mam-
malian fibroblast cell line, baby hamster kidney cells
(BHK) [3, 4, 7].
Safety in animal model 
The mouse encephalitis model is well established for
several alphaviruses, although it generally lacks the ability
to reproduce the vascular component of the disease that is
typical for EEE in humans. A murine model for VEEV-in-
duced encephalitis and lymphotropism is well established
[4, 5, 9—12]. Experimental studies have demonstrated that
VEEV infection results in biphasic disease, which starts
with productive infection of lymphoid tissue and ends in
the destruction of the CNS caused by very efficient viral
replication and a »toxic« neuroinflammatory response. By
the time encephalitis has developed, infectious virus is usu-
ally absent from peripheral organs and blood. However,
virus replicates to high titers in the brain and encephalitic
mice die within 5—7 days of infection. This classical mouse
model is useful to study the mechanisms of pathogenesis in
mice and to evaluate vaccine (and antiviral drug) efficacy
because CNS infection consistently occurs in naive mice
and is uniformly fatal [4, 12]. Recently, this experimental
approach has been used in mice with selective immunode-
ficiencies to facilitate studies of VEEV clearance from the
brain and also provides additional safety data for these vac-
cines [6]. 
Safety in immunocompetent mice
VEEV vaccines
The safety of several chimeric SIN/VEE virus vaccine
candidates have been tested in mice of different genetic
background and age, and via several routes of infection. All
were evaluated in parallel with the investigational vaccine,
TC83, which is currently used for vaccination of research
and military personnel, but which is documented to have
significant adverse effects. SIN83 chimeric virus at doses
in range of 2 × 104 to 2 × 106 PFU  did not cause any detec-
table clinical disease in either adult or weanling mice when
monitored up to 21 days after either s.c. or i.c. inoculation
[4].  When tested at a higher s.c. dose of 5 × 106 PFU, none
of the chimeric SIN/VEE virus, e.g., SIN83, SIN/ZPC, or
SIN/TRD resulted in morbidity or mortality [5]. This is in
contrast to mortality of 10 % and 100 % for TC83, which
were both fatal to newborn outbred (NIH Swiss) mice at
comparable doses of 2 × 105 and 5 × 106, respectively [4, 7].
Another VEEV vaccine candidate undergoing preclinical
testing, V3526, was 100% fatal to these mice at the lower
dose of 1 × 105 [7]. Further, TC83 was 100 % fatal by i.c. in-
oculation at the higher doses (2 × 105 and 2 × 106); although
at the lower dose, TC83 was not lethal for majority of the
mice, it caused neurological sequelae (ataxia, paralysis)
and weight loss in 33—44 % of the mice [4]. Similarly, in
adult inbred (C57BL/6) mice, no deaths were observed in
mice that received two doses of 5 × 105 PFU approximate-
ly one month apart and monitored for a total of 42 days [6].
EEEV vaccines
The safety of the chimeric SIN/EEEV vaccines were
evaluated in 8-week-old, female NIH Swiss mice inoculat-
ed subcutaneously with doses in the range of 3.7—5.8
log10 PFU per animal. Both of the chimeric SIN/EEE virus
strains (SIN/NAEEEV and SIN/SAEEEV) were highly at-
tenuated in mice, evidenced by the lack of neurological dis-
ease, febrile response, or significant weight loss, although
intracraneal inoculation of weanling (6-day-old) NIH
Swiss mice with these vaccines in the same dose range (5
log10 PFU) resulted in higher neurovirulence than the s.c.
route, but with delayed kinetics for SIN/SAEEEV in com-
parison to the parental SAEEEV [3].
Safety in immunodeficient mice
VEEV vaccines have been evaluated for safety in im-
munodeficient mice developed on the C57BL/6 back-
ground. We selected the chimeric SIN/ZPC virus as a
promising vaccine candidate for further examination of its
safety in inbred mice with selective immunodeficiencies in
the T cell compartments (αβ T cell receptor (TCR)-defi-
cient or γδTCR-deficient mice), in the B cell compartment
(μMT-deficient mice), or in their ability to respond to the
cytokine interferon gamma (IFN-γR-deficient mice).
Vaccines were delivered via two s.c. inoculations (5 × 105
PFU/animal) and survival evaluated for 14 days following
the booster dose [6]. All alpha-beta (αβ) TCR- and γδTCR-
-deficient, and μMT-deficient mice survived vaccination
and none of these animals showed any signs of disease.
93 % of IFN-γR-deficient mice survived vaccination. The
deaths of 2/30 animals occurred suddenly without any pre-
vious signs typical of VEE (anorexia and/or paralysis), no
infectious virus could be isolated from their brains of the
two animals, thus it is suggested that the overall poor health
status of these animals was a contributing factor [6].
Immunogenicity & efficacy
VEEV vaccines
To evaluate the immunogenicity and efficacy of the
chimeric SIN/VEE virus, we have utilized as challenge
virus the ZPC738 strain, a 1997 sentinel hamster isolate
from Venezuela [13] that is characterized as an enzootic
subtype ID strain, [5], which is uniformly lethal in naive
outbred (NIH Swiss) mice by 7 days after intranasal (i.n.)
inoculation of 2 × 105 PFU/animal [5]. Immunodeficient
mouse strains were similar in their susceptibility to disease
development and death following VEEV infection, with
disease observed between 6 and 8 days following infection
with the parental VEEV strain (ZPC738) infection, as ob-
served for the parental (C57BL/6) immunocompetent mice
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[14]. Therefore, these strains also represent a valid alterna-
tive vaccination/challenge model for chimeric SIN/VEE
virus and have enabled us to examine different immune ef-
fector mechanisms.
Immunogenicity
Immunocompetent newborn [4] and adult NIH Swiss
[5] as well as adult C57BL/6 [6] mice consistently devel-
oped neutralizing antibody (PRNT80 titer > 20), although
the titers varied, depending upon the number of vaccina-
tions [5], the vaccine dose [4, 5], the time post-vaccination
[5], and the chimeric virus evaluated. In contrast, immun-
odeficient (C57BL/6) mice vary considerably in their abil-
ity to develop VEEV-specific neutralizing antibody, and
antibody titers did not correlate with disease development
and survival outcomes [6], but are likely to depend upon the
selective nature of the immunodeficiency related to ab-
sence of mature B cells (e.g., in  μMT mice) or to priming
deficiencies (e.g., lack of T and B cell interactions in αβ
TCR- and to a lesser extent, in IFN-γR — and γδTCR-defi-
cient mice).
Efficacy
The chimeric SIN/VEE vaccines were highly effica-
cious in newborn and adult NIH Swiss as well as in
C57BL/6 mice challenged with ZPC738, as described
above, irrespective of the challenge method (i.c., i.n., or
s.c.) [4—6]. Efficacy studies were first performed using the
chimeric SIN83 vaccine in 6-day-old NIH Swiss mice.
SIN83 provided 100 % protection against lethal s.c. chal-
lenge and did not develop clinical symptoms of disease at
any time during the 2 month observation period, regardless
of the dose of SIN83 used for immunization (in the range of
103—106 PFU) [4], although mice were only partially pro-
tected against i.n. and i.c. challenges with high doses of
ZPC738 [5].
Protection studies using the chimeric SIN/ZPC vaccine
were performed in adult immunocompetent C57BL/6
(wild type, WT) mice and their immunodeficient counter-
parts, as described for safety studies. Several replicate ex-
periments with observation over a 28 day period following
challenge with ZPC738 were carried out. None of the αβ
TCR-deficient mice survived challenge mock-vaccinated
WT mice (0 of 18; 2 replicates; 0 %). Vaccinated γδ TCR-
-deficient mice were protected, with survival of 98 %,
which was significantly greater (Fisher's exact test; p =
= 0.0001) than for vaccinated WT mice (93%). Survival of
IFN-γR KO mice was reduced in comparison to vaccinated
WT and γδ TCR KO mice, although the survival time was
also extended in comparison to mock-vaccinated and vac-
cinated αβTCR-deficient mice. The majority of μMT-defi-
cient mice were not protected from challenge (13% sur-
vival) and this was not significantly different from mock
vaccinated WT mice (Fisher's exact test; p = 0.2748) [6]. In
addition to survival analysis, virus titers in the brain and pe-
ripheral organs of vaccinated, challenged immunodeficient
mice were evaluated as a marker of protection. At day 3
post-challenge, viral titers in the brain and peripheral tis-
sues of wild type vaccinated mice were uniformly low and
at day 7 post-challenge, were undetectable, in contrast to
mock-vaccinated wild type mice. For vaccinated immun-
odeficient mice, high levels of infectious virus were detect-
ed in all tissues at either day 3 or day 7, with the highest
titers in the brain at day 7 post-challenge [6].
EEEV vaccines
EEEV vaccine candidates were evaluated in outbred
(NIH Swiss) mice using as challenge virus the NA strain
FL93—939 (106 PFU/animal via intraperitoneal route, i.p.),
which causes clinical encephalitis by day 3—4 and is uni-
formly lethal to mice by day 4—5 [3]. Mice were vaccinated
with doses in the range of 3.7—5.7 or 3.8—5.8 log10 PFU  10
for NA and SA based chimeric virus (respectively) via sub-
cutaneously route and challenged (106 PFU/i.p.). The chi-
meric SIN/NAEEEV and SIN/SAEEEV vaccines provided
100 % protection for both vaccines/all doses tested, with
the exception of the low dose SIN/SAEEEV, which pro-
tected 80 % of the mice. These survival outcomes correlat-
ed with the development of detectable IgG antibodies in
vaccinated mice. The antibody titer, as determined via pla-
que reduction neutralization test as well as ELISA, showed
a dose response to SIN/NAEEEV, with the highest mean
titers resulting from immunization with 5.7 log10 PFU and
the SIN/NAEEEV (5.7 log dose) elicited cross-reactive
neutralizing antibodies against the SA EEEV strain, albeit
at a relatively lower titer. At the lowest SIN/NAEEEV dose
(3.7 log10 PFU), 70 % of the mice had detectable PRNT
titer against homologous virus, but among those that were
negative (3/10), one had a positive IgG titer by ELISA.
Future directions
Ongoing VEEV studies enable us to dissect the features
of the immune response and its relationship to the patho-
genesis of the virulent VEEV as well as to understand the
basis of the protection elicited by chimeric SIN/VEE virus-
es. This approach also has application to other neuroviru-
lent viruses for which little or no treatment or vaccination
options are available. Currently, we are developing and
evaluating chimeric SINV-based vaccines against Rift
Valley Fever virus (RVFV) [15] and highly pathogenic
avian influenza A/H5N1 (Paessler, unpublished). 
Mechanisms of protection against VEE
Protection in immunodeficient mice provide insight in-
to the mechanism of protection, which appears to be medi-
ated predominantly via selective T cell population [6]. This
is suggested by reconstition of protection in αβ TCR-defi-
cient mice by transfer of bulk CD3+ T cells using an adop-
tive transfer approach performed using VEEV-specific T
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cells isolated from the spleens of SIN/ZPC-vaccinated
donor C57BL/6  mice. Transfer of these cells into αβTCR-
-deficient mice resulted in restoration of protection from
lethal encephalitis that was not observed in the mock-trans-
fered mice.
Chimeric SIN/RVFV vaccines
Several recombinant SIN/RVFV viruses were designed
to express large fragments containing the segments of het-
erologous RVFV proteins, e.g., E2-RVFV envelope glyco-
protein Gn fusion proteins, on the surface of chimeric, in-
fectious viral particles or secreted from infected cells [15].
Gn was efficiently expressed by these chimeric SIN/RVFV
constructs, could be produced in cell culture, albeit at a re-
duced efficiency compared to constructs expressing other
heterologous genes, and were subsequently evaluated in
mice for their ability to induce protection against RVFV
(ZH501strain) challenge. Mice were immunized once or
twice with 5 × 106 PFU of the recombinant viruses that ex-
pressed either a secreted form of RVFV Gn or E2-Gn frag-
ments, and challenged via s.c. with 5 × 103 PFU of RVFV
ZH501. All of the constructs induced at least partial protec-
tion against the challenging virus, and a second booster
dose increased protection. Chimeric viruses containing
VEEV or SINV-E2 fused in the amino terminus with the
318-a.a.-long fragment of RVFV Gn were the most effica-
cious among the constructs tested, and mice developed no
clinical signs of the disease. Ongoing studies focus on the
improved production of these viruses.
Conclusions
Chimeric alphavirus-based vaccines represent an im-
portant advance in vaccine development for a number of in-
fectious pathogens, as Sindbis replicon particles have been
shown to be safe and effective for the induction of both cell-
-mediated and humoral immune responses [16]. As summa-
rized in this review, SIN/VEE and SIN/EEE vaccines have
proven to be safe in all animal models tested to date, e.g.,
newborn and adult outbred mice, adult inbred immuno-
competent and immunodeficient mice, as well as hamsters.
Significantly, the alphavirus vaccines are immunogenic
and efficacious in outbred and inbred immunocompetent
and immunodeficient animals [3]. Other preclinical studies
of SIN-based influenza A/H5N1 vaccines have demon-
strated efficacy in the Balb/C mouse model (Paessler, un-
published). This approach is an intense focus of investiga-
tion for the development of vaccines against specific
pathogens as well as the optimization of delivery methods
and adjuvant augmentation of immune responses [17—22].
For VEEV studies, this vaccine approach has led to the de-
velopment of a unique model for studying the persistence
of attenuated variants of VEEV in the brains of chimeric
SIN/VEE vaccinated, VEEV-challenged γδ TCR deficient
mice, which survive and do not develop clinical disease [6].
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